Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function

Trial Profile

Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Basiliximab
  • Indications Delayed graft function
  • Focus Therapeutic Use
  • Acronyms PREDICT-DGF
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jun 2017 Planned End Date changed from 1 Feb 2018 to 1 Oct 2017.
    • 08 Jun 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top